F-Prime

F‑Prime’s investment thesis is built around two pillars—healthcare and technology—unified by a belief that technical excellence, strong operators, and large addressable markets generate lasting value. In healthcare, they invest across therapeutics, medtech, and health‑tech services without a fixed stage constraint, backing companies that show compelling pre‑clinical or early clinical data, clear IP, and a pathway to regulatory approval. Their backing of ARTBIO’s radiopharmaceutical platform exemplifies willingness to fund modality‑shifting science when outcome impact is clear. In technology, the focus is on enterprise software, fintech, and frontier areas such as robotics, where advances in AI, automation, or hardware costs can be turned into workflow‑integrated products. The firm prefers “vertical” solutions that solve specific productivity gaps and demonstrates disciplined capital efficiency. Geographically, F‑Prime is global, with offices in Cambridge, London, and San Francisco, and investments spanning the Americas, Europe, and Asia. They avoid hype‑driven segments lacking commercial traction—such as autonomous vehicles without revenue models—and steer away from projects that offer incremental scientific improvements without step‑change outcomes. The core belief is that value accrues to teams that pair differentiated technical or clinical advantage with measurable commercialization metrics and capital‑efficient growth.

F‑Prime’s investment decisions are anchored in an evidence‑driven framework that heavily weights the founding team’s domain expertise and execution track record. A compelling, quantifiable market need and early validation—whether through pilot customers in tech or pre‑clinical data in life sciences—are required before they commit capital. Traction is measured by concrete outcomes: product usage by large enterprises, clinical milestones, or clear ROI for services. Deal‑breakers include technologies with no clear go‑to‑market path, hype‑driven sectors lacking commercial proof (e.g., autonomous vehicles without revenue), and scientific programs that do not promise a step‑change in outcomes. The firm balances technical risk with commercial risk, favoring “vertical” solutions that can demonstrate early revenue or clinical impact while remaining open to backing exceptional teams at any stage.

• SnapdocsLead
  Vertical SaaS digitizing mortgage closings with AI-driven workflow; matches F-Prime’s vertical SaaS + payments/platform thesis.
• PatientPingLead
  Health-tech care-coordination platform lowering costs by connecting providers; fits F-Prime’s services/HCIT thesis. F-Prime led seed and co-led Series A.
• SpinwheelLead
  Fintech infrastructure providing high-coverage consumer liability data; aligns with F-Prime’s data/infra focus. F-Prime led the $30M Series A.
• KanastraLead
  Private-credit infrastructure modernising capital-markets workflows; consistent with F-Prime’s capital-markets/infra thesis. F-Prime led the $30M Series B.
• VestwellLead
  Modern retirement platform for advisors; core fintech infrastructure theme. Series A led by F-Prime.
• Deal EngineLead
  Vertical SaaS for travel-industry deal management; aligns with F-Prime’s vertical software thesis. Seed round led by F-Prime.
• CurvanceLead
  DeFi/liquidity infrastructure in crypto; fits F-Prime’s frontier/crypto focus. Strategic round co-led by F-Prime and Primal.
• Flywire
  Global payments infrastructure solving complex cross-border receivables; emblematic fintech/payments thesis. F-Prime was an early backer but did not lead disclosed rounds.
• Toast
  Vertical SaaS + payments platform for restaurants; quintessential example of F-Prime’s vertical SaaS thesis. F-Prime participated in the first institutional round but did not lead.

• 
  Bessemer Venture Partners

  Toast
• 
  Primary Venture Partners

  Vestwell